Logo

Bayer, NovaDx Enter $3M Gene Research Deal

Nov 21, 1998
Premium

VANCOUVER, BC--NovaDx International and its wholly-owned subsidiary Proteomix here entered into an agreement with German chemical and pharmaceutical company Bayer under which NovaDx will identify a series of osteoporosis genes. Bayer will pay up to $3 million to NovaDx based upon the successful completion of research milestones, and NovaDx will give Bayer access to a series of novel osteoclast-specific genes that may be potentially useful as drug targets for metabolic bone disease.

Filed under

Informatics
Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.